
|Articles|October 20, 2008
Novel glaucoma solution enters trials
INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.
Advertisement
INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.
The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).
This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
3
Oku Digital Health launches from Topcon to link eye care, primary care
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















